EpiBiologics closed a $107 million Series B led by GV and Johnson & Johnson’s venture arm to advance its EpiTAC platform and lead bispecific degrader EPI‑326 into first‑in‑human studies. The Bay Area biotech plans to start trials in mid‑2026 in EGFR‑driven non‑small cell lung cancer and head‑and‑neck cancers. The company’s approach uses bispecific antibodies to tag extracellular tumor proteins for lysosomal degradation, a twist on targeted protein degradation focused on cell‑surface targets. EpiBiologics’ executives highlighted a favorable preclinical safety profile and the opportunity to combine degraders with standard therapies to overcome resistance. The financing drew strategic participation from prominent corporate VCs and life‑science investors, reflecting broader investor enthusiasm for next‑generation protein‑degradation modalities.